Nykode gets back rights VB10.NEO program from Genentech

12 November 2024

Norwegian clinical-stage biotech Nykode Therapeutics (OSE: NYKD) revealed that it has received notification from Genentech, a US subsidiary of Roche (ROG: SIX), of its decision to terminate the collaboration and licensing agreement for Nykode’s VB10.NEO cancer vaccine program.

With this notice, the existing collaboration and licensing agreement signed September 2020 will terminate effective January 6, 2025 and Nykode will regain control of VB10.NEO and its intellectual property portfolio along with rights to license the program.

Nykode is not required to refund any upfront payments or make any future payments to Genentech on the termination, but its shares dropped around 5% on the news.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK